Pramlintide
- Atc Codes:A10BX05
- CAS Codes:196078-30-5
- PHARMGKB ID:196078-30-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Symlin.
Drug combinations
Chemistry
Pramlintide Acetate: C~171~H~267~N~51~O~53~S~2~ xC~2~H~4~O~2~ yH~2~O. Mw: 3949.40. (1) 25-L-Proline-28-L-proline-29-L-prolineamylin (human) acetate, hydrate; (2) L-Lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-L-tyrosinamide, cyclic (2→7)-disulfide, acetate, hydrate. CAS-196078-30-5 (1997).
Pharmacologic Category
Antidiabetic Agents; Amylinomimetics. (ATC-Code: A10BX05).
Mechanism of action
Reduces postprandial glucose increases via prolongation of gastric emptying time, reduction of postprandial glucagon secretion, and reduction of caloric intake through centrally-mediated appetite suppression.
Therapeutic use
Adjunctive treatment with mealtime insulin in type 1 diabetes mellitus (insulin-dependent). Adjunctive treatment with mealtime insulin in type 2 diabetes mellitus (non-insulin-dependent).
Pregnancy and lactiation implications
Caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to pramlintide or any component of the formulation. Confirmed diagnosis of gastroparesis. Hypoglycemia unawareness.
Warnings and precautions
Avoid use in conditions or concurrent medications likely to impair gastric motility (e.g. anticholinergics). Do not use in patients requiring medication(s) to stimulate gastric emptying. Use with caution in history of nausea, and in neuropathic conditions which may mask signs/symptoms of hypoglycemia. Use caution with certain antihypertensive agents (e.g. β-adrenergic blockers) which may mask signs/symptoms of hypoglycemia. Co-administration with insulin may induce severe hypoglycemia (usually within 3 hours following administration). Concurrent use of other glucose-lowering agents may increase risk of hypoglycemia. Do not use in HgbA~1c~ levels >9% or recent, recurrent episodes of hypoglycemia. Use caution in visual or dexterity impairment.